INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices [1] - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission related to disclosures about its prostate cancer therapeutic candidates, leading to a significant drop in its ADR price [3] Group 1 - The investigation by Pomerantz LLP focuses on whether Telix and its officers or directors have engaged in unlawful business practices [1] - Following the SEC subpoena, Telix's ADR price fell by $1.70, or 10.44%, closing at $14.58 on July 23, 2025 [3]